Advanced Lung Disease Conference

December 7, 2018 - December 8, 2018

Program Overview

The Advanced Lung Disease: Novel Therapies and Controversies Conference will have engaging state-of-the-art multidisciplinary lectures focused on the causes diagnosis, prevention, and treatment of diseases affecting the lungs, including cystic fibrosis, COPD, Interstitial Lung Disease, pulmonary hypertension and adult congenital heart diseases. The course will also feature panel sessions to provide clinicians the opportunity to discuss specific treatment challenges, the role of the caregivers, transplant coordinators and logistics of transplantation and methods that will be useful in their practices.

Advanced lung diseases affects a large part of the population and contributes significantly to morbidity and mortality. Novel therapies for diseases such as cystic fibrosis, COPD, InterstitialLung Disease, pulmonary hypertension and adult congenital heart diseases have given patients a chance at a new and healthier life. Transplantation is a major part of the innovation for providing these patients a new lease on life, but there are many steps and considerations along the way that can add to quality life years. The conference seeks to provide practitioners, trainees, patients and associated staff with a look at the horizon of advanced lung therapies. Novel therapies such as ex vivo lung perfusion, airway stenting, biopsies, gene therapy, stem cells, bronchial valves and lung volume reduction therapy will be discussed. Break out sessions will discuss the role of the caregivers, transplant coordinators and logistics of transplantation.

Novel Therapies and Controversies

Course Directors Gabriel Loor, MD and Amit D. Parulekar, MD, MS

Target Audience

This activity is designed for pulmonologists, transplant pulmonologists, respiratory therapists, internal medicine physicians, thoracic surgeons, critical care specialists, general surgeons, nurses, residents, fellows, physician assistants and nurse practitioners who are interested in optimizing their pulmonary outcomes.

CME Learning Objectives & Credit Designtation


Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Texas Heart Institute designates this live activity for a maximum of14.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Designation

Up to 12.83 contact hours will be awarded for successful completion of this activity. To receive a certificate of completion with awarded contact hours, you are required to sign-in at registration each day, attend the entire program or partially for topics listed on the Tracker and return the completed evaluation form each day.

Learning Objectives

Describe the background and evolution of individual pulmonary diseases, the evolving management strategies, and controversies.

Understand the workup for lung or heart-lung transplantation and the role of extracorporeal membrane oxygenation in acute exacerbations or as an adjunct to transplantation.

Stress detailed operative descriptions of each presenter’s approaches to pulmonary care.

Provide valuable insight through video education and interactive panels of pulmonologists.

Event Location

Four Seasons Hotel Houston

1300 Lamar Street Houston, TX 77010 United States
(713) 650-1300